Press Releases
Contract win for new stroke study
New therapeutic area, broadening IXICO’s neurological footprint IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has executed a contract to provide neuroimaging services for a new clinical trial for acute ischemic stroke with its largest pharma client.
Read more
Collaboration with Microsoft to support business scale up with global pharma
IXICO plc, the AI data analytics company delivering insights in neuroscience, announces a collaboration with Microsoft to develop its AI data analytics platform for the global pharmaceutical industry.
Read more
IXICO chosen for new Phase II Alzheimer’s disease study
IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been selected by a current mid-sized biopharmaceutical client to support the company’s Phase II Alzheimer’s disease clinical trial.
Read more
IXICO selected by Cyclerion for new Alzheimer’s disease study
IXICO plc, the AI data analytics company delivering insights in neuroscience, announces that it has been selected by Cyclerion Therapeutics, Inc. , a new client, to support the company’s Phase IIa clinical trial to investigate CY6463 for treatment of individuals with Alzheimer’s disease.
Read more
IXICO attending AD/PD 2021 Conference
IXICO will be presenting at the upcoming AD/PD 2021 conference taking place virtually on 9-14 March 2021. AD/PD 2021, the 15th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, is one of the most prestigious in the year and IXICO welcomes the opportunity to present.
Read more
IXICO secures new contract for £3.4 million
IXICO broadens its rare disease franchise into SCA3, a rare neurodegenerative condition IXICO plc, the AI data analytics company delivering insights in neuroscience, announces it has been awarded a £3. 4 million contract to run over c. 4. 5 years by an existing client for a Spinocerebellar Ataxia type 3 (SCA3) trial.
Read more
IXICO selected by new large global pharma for orphan drug clinical trial
IXICO plc, the AI data analytics company delivering insights in neuroscience, has secured a contract for neuroimaging solutions with a new, large global pharmaceutical company. The Phase IIB trial will investigate an orphan drug designated clinical asset for the treatment of Huntington's disease.
Read more
IXICO announces £1.9 million new study award
IXICO plc, the AI data analytics company delivering insights in neuroscience, today announces that it has executed a contract to provide neuroimaging services that will support a phase Ib/II clinical trial for Huntington’s disease.
Read more1-8 of 44 results